scholarly journals Clinical significance of circulating tumor cells after chemotherapy in unresectable pancreatic ductal adenocarcinoma

2022 ◽  
Vol 16 ◽  
pp. 101321
Author(s):  
Hyemin Kim ◽  
Chan Mi Heo ◽  
Jinmyeong Oh ◽  
Hwe Hoon Chung ◽  
Eun Mi Lee ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Clinical Significance ◽  
Ductal Adenocarcinoma

scholarly journals High Clinical Value of Liquid Biopsy to Detect Circulating Tumor Cells and Tumor Exosomes in Pancreatic Ductal Adenocarcinoma Patients Eligible for Up-Front Surgery

Cancers ◽  
2019 ◽  
Vol 11 (11) ◽  
pp. 1656 ◽  
Author(s):  
Etienne Buscail ◽  
Catherine Alix-Panabières ◽  
Pascaline Quincy ◽  
Thomas Cauvin ◽  
Alexandre Chauvet ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Liquid Biopsy ◽  
Neoadjuvant Treatment ◽  
Digital Pcr ◽  
Portal Blood ◽  
Ductal Adenocarcinoma ◽  
Clinical Value ◽  
Liquid Biopsies

Purpose: Expediting the diagnosis of pancreatic ductal adenocarcinoma (PDAC) would benefit care management, especially for the start of treatments requiring histological evidence. This study evaluated the combined diagnostic performance of circulating biomarkers obtained by peripheral and portal blood liquid biopsy in patients with resectable PDAC. Experimental design: Liquid biopsies were performed in a prospective translational clinical trial (PANC-CTC #NCT03032913) including 22 patients with resectable PDAC and 28 noncancer controls from February to November 2017. Circulating tumor cells (CTCs) were detected using the CellSearch® method or after RosetteSep® enrichment combined with CRISPR/Cas9-improved KRAS mutant alleles quantification by droplet digital PCR. CD63 bead-coupled Glypican-1 (GPC1)-positive exosomes were quantified by flow cytometry. Results: Liquid biopsies were positive in 7/22 (32%), 13/22 (59%), and 14/22 (64%) patients with CellSearch® or RosetteSep®-based CTC detection or GPC1-positive exosomes, respectively, in peripheral and/or portal blood. Liquid biopsy performance was improved in portal blood only with CellSearch®, reaching 45% of PDAC identification (5/11) versus 10% (2/22) in peripheral blood. Importantly, combining CTC and GPC1-positive-exosome detection displayed 100% of sensitivity and 80% of specificity, with a negative predictive value of 100%. High levels of GPC1+-exosomes and/or CTC presence were significantly correlated with progression-free survival and with overall survival when CTC clusters were found. Conclusion: This study is the first to evaluate combined CTC and exosome detection to diagnose resectable pancreatic cancers. Liquid biopsy combining several biomarkers could provide a rapid, reliable, noninvasive decision-making tool in early, potentially curable pancreatic cancer. Moreover, the prognostic value could select patients eligible for neoadjuvant treatment before surgery. This exploratory study deserves further validation.

scholarly journals A model for the detection of pancreatic ductal adenocarcinoma circulating tumor cells

2018 ◽  
Vol 5 (3) ◽  
pp. 97 ◽  
Author(s):  
Matthew S. Alexander ◽  
Brianne R. O'Leary ◽  
Devon Moose ◽  
Juan Du ◽  
Michael D. Henry ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Ductal Adenocarcinoma

scholarly journals Doublecortin-Like Kinase 1 Is Elevated Serologically in Pancreatic Ductal Adenocarcinoma and Widely Expressed on Circulating Tumor Cells

PLoS ONE ◽  
2015 ◽  
Vol 10 (2) ◽  
pp. e0118933 ◽  
Author(s):  
Dongfeng Qu ◽  
Jeremy Johnson ◽  
Parthasarathy Chandrakesan ◽  
Nathaniel Weygant ◽  
Randal May ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Ductal Adenocarcinoma

scholarly journals Neutrophils assist the metastasis of circulating tumor cells in pancreatic ductal adenocarcinoma

Medicine ◽  
2016 ◽  
Vol 95 (39) ◽  
pp. e4932 ◽  
Author(s):  
Lianyuan Tao ◽  
Lingfu Zhang ◽  
Ying Peng ◽  
Ming Tao ◽  
Lei Li ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Ductal Adenocarcinoma

scholarly journals Detection of circulating tumor cells in blood of pancreatic ductal adenocarcinoma patients

2020 ◽  
Author(s):  
Andrea Mayado ◽  
Alberto Orfao ◽  
Anouk Mentink ◽  
Maria L. Gutierrez ◽  
Luis Muñoz-Bellvis ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Ductal Adenocarcinoma

scholarly journals Circulating Tumor Cells, Circulating Tumor DNA and Other Blood-based Prognostic Scores in Pancreatic Ductal Adenocarcinoma – Mini-Review

In Vivo ◽  
2021 ◽  
Vol 35 (1) ◽  
pp. 31-39
Author(s):  
MARIAN LIBERKO ◽  
KATARINA KOLOSTOVA ◽  
ARPAD SZABO ◽  
ROBERT GURLICH ◽  
MARTIN OLIVERIUS ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Circulating Tumor Dna ◽  
Prognostic Scores ◽  
Ductal Adenocarcinoma ◽  
Tumor Dna

Clinical significance of circulating tumor cells identified by cell-surface vimentin in pancreatic cancer.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e14562-e14562
Author(s):  
Tao Wei ◽  
Qi Zhang ◽  
Tingbo Liang ◽  
Xueli Bai
Keyword(s):  
Pancreatic Cancer ◽  
Cell Surface ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Clinical Significance ◽  
Ductal Adenocarcinoma ◽  
Rank Test ◽  
Epithelial Tumor ◽  
Mesenchymal Phenotype

e14562 Background: Identification of circulating tumor cells (CTCs) largely rely on epithelial tumor cell marker. Here we sought to interrogate whether cell-surface vimentin could be a biomarker for isolating CTCs potentially with mesenchymal phenotype in pancreatic ductal adenocarcinoma (PDAC). Methods: In total, 100 PDAC patients, 16 patients with intraductal papillary mucinous neoplasm (IPMN), and 30 healthy individuals were enrolled between December 2016 and November 2017. Potential CTCs were captured in 4 ml blood samples by vimentin antibody-coated microfluidic chip. CTCs were defined as vimentin+CD45-Hoechst+. Results: In vitro experiment showed that vimentin was highly expressed on the surface of pancreatic tumor cells with mesenchymal phenotype. Overall, vimentin+ CTCs were detected in 76% of patients with PDAC, but only in 2 out 30 healthy donors. Besides, five patients (31.3%) with IPMN had vimentin+ CTCs, and 10 CTCs were identified in one case. Using a cut-off value of two cells/4 ml of blood, 65% PDAC patients were positive for vimentin+ CTCs , while the positivity rates for the patients with IPMN and the healthy controls were 25% and 0%, respectively. Combined vimentin+ CTCs and CA19-9 offered a favorable diagnostic potency with area under curve of 0.968. Vimentin+ CTCs counts correlated with change of tumor burden for patients undergoing resection ( P < 0.01). Significant reduction of CTCs counts was observed after chemotherapy for subjects responding to treatment ( P < 0.05). The paired analysis showed that CTC counts was higher in portal vein blood than peripheral blood for 10 patients with available samples ( P < 0.05). Patients with 2 or more CTCs detected had more advanced disease and poorer differentiated tumor. In addition, preoperative higher CTCs counts correlated with shortened recurrence-free survival (Log-rank test: P = 0.02). Conclusions: Vimentin+ CTCs serves as a reliable biomarker in pancreatic cancer. The enrichment of potential mesenchymal CTCs could complement the strategy capturing epithelial CTCs, and provides a way to more thoroughly interrogate the biology and clinical significance of CTCs in PDAC.

scholarly journals Expression Profiling of Circulating Tumor Cells in Pancreatic Ductal Adenocarcinoma Patients: Biomarkers Predicting Overall Survival

2019 ◽  
Vol 9 ◽  
Author(s):  
Consuelo Amantini ◽  
Maria Beatrice Morelli ◽  
Massimo Nabissi ◽  
Francesco Piva ◽  
Oliviero Marinelli ◽  
...  
Keyword(s):  
Overall Survival ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Expression Profiling ◽  
Ductal Adenocarcinoma
Sign in / Sign up

Export Citation Format

Share Document